{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:44:17Z","timestamp":1767897857112,"version":"3.49.0"},"reference-count":112,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>A noteworthy shift from class I to class III antiarrhythmic agents for suppression of atrial fibrillation has occurred. Sotalol, amiodarone, and dofetilide have been evaluated for their ability to maintain sinus rhythm in patients with chronic atrial fibrillation. All of these agents are moderately effective; however, amiodarone appears to be most efficacious. Aside from their common class III actions, these agents have profoundly different pharmacologic, pharmacokinetic, safety, and drug interaction profiles that help guide drug selection. Amiodarone and dofetilide are safe in patients who have had a myocardial infarction and those with heart failure. The safety of commercially available d,l\u2010sotalol in these patients is poorly understood. Torsades de pointes is the most serious adverse effect of sotalol and dofetilide, and risk increases with renal dysfunction. Amiodarone has minimal proarrhythmic risk but has numerous noncardiac toxicities that require frequent monitoring. Overall, an ideal antiarrhythmic agent does not exist, and drug selection should be highly individualized.<\/jats:p>","DOI":"10.1592\/phco.21.20.1514.34484","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T05:27:33Z","timestamp":1086758853000},"page":"1514-1529","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Review of Class III Antiarrhythmic Agents for Atrial Fibrillation: Maintenance of Normal Sinus Rhythm"],"prefix":"10.1002","volume":"21","author":[{"given":"James P.","family":"Tsikouris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig D.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430050045005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90363-8"},{"key":"e_1_2_1_4_2","first-page":"172","article-title":"Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age","volume":"37","author":"Hill JD","year":"1987","journal-title":"J R Coll Gen Pract"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/jama.1981.03310400022019","article-title":"Mortality in an insured population with atrial fibrillation","volume":"245","author":"GaJewishi J","year":"1981","journal-title":"JAMA"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198204293061703"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation: pharmacological intervention in atrial fibrillation (PIAF)\u2014a randomized trial","volume":"356","author":"Hohnloser SH","year":"2000","journal-title":"Lancet"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00082-9"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.4.1106"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241201"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(59)90274-1"},{"key":"e_1_2_1_13_2","first-page":"265","volume-title":"Cardiac electrophysiology of arrhythmias","author":"Allessie MA","year":"1985"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.39.020188.000353"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090041008"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90352-D"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90982-I"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198211000-00008"},{"key":"e_1_2_1_19_2","first-page":"817","article-title":"Comparative \u03b2\u2010blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs","volume":"232","author":"Gomoll AW","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00449-3"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00147-7"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(97)70186-8"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0011-393X(95)85125-9"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00189-2"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90511-A"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90649-A"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.6.1932"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00025-8"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1998.tb01105.x"},{"issue":"4","key":"e_1_2_1_30_2","first-page":"S51","article-title":"Inotropy and class III antiarrhythmic activity: d\u2010sotalol in experimental heart failure","volume":"21","author":"Mortensen E","year":"1992","journal-title":"J Mol Cell Cardiol"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90197-9"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00710-8"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(83)90002-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(84)80367-8"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702193160807"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1992.tb00972.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00584702"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.4.948"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(84)90451-4"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(88)90481-4"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1970.tb09891.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90300-5"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/clinchem\/35.9.1882","article-title":"Amiodarone and the thyroid","volume":"35","author":"Kennedy RL","year":"1989","journal-title":"Clin Chem"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0033-0620(89)90033-9"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1386"},{"key":"e_1_2_1_46_2","first-page":"771","article-title":"Pharmacodynamic studies of amiodarone and its active N\u2010desethyl metabolite","volume":"8","author":"Nattel S","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.75.1.265"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00235524"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109033051002"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00452-3"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.64.6.1167"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.eurheartj.a062057","article-title":"Amiodaroneinduced torsade de pointes","volume":"7","author":"Brown MA","year":"1986","journal-title":"Eur Heart J"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.81.3.384"},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/oxfordjournals.eurheartj.a062315","article-title":"Torsade de pointes during loading with amiodarone","volume":"8","author":"Leroy G","year":"1987","journal-title":"Eur Heart J"},{"key":"e_1_2_1_55_2","first-page":"411","article-title":"Amiodarone induced torsade de pointes: report of three cases and review of literature","volume":"44","author":"Jorens PG","year":"1989","journal-title":"Acta Cardiol"},{"key":"e_1_2_1_56_2","first-page":"SI\u2010373","article-title":"Differential effects of acute and chronic administration of amiodarone on E\u20104031\u2010sensitive component (iKr) and chromanol 293B\u2010sensitive component (iKs) on the delayed rectifier potassium current in rabbit ventricular myocytes [abstr]","volume":"98","author":"Kamiya K","year":"1998","journal-title":"Circulation"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb09804.x"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411201"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03402-4"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03926.x"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05572.x"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199303000-00024"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.suppl_H.30"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90196-8"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600620303"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1976.tb03162.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1979.tb02515.x"},{"key":"e_1_2_1_68_2","first-page":"S38","article-title":"Basic review and comparison of \u03b2\u2010blocker pharmacokinetics","volume":"28","author":"Sundquist H","year":"1980","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_69_2","first-page":"41","article-title":"A review of the clinical pharmacokinetics of amiodarone","volume":"6","author":"Paton DM","year":"1984","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_1_70_2","first-page":"636","article-title":"Amiodarone: current perspectives from Europe","volume":"16","author":"Robinson KC","year":"1987","journal-title":"Heart Lung"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.22"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(83)90006-6"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.72.5.1064"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(10)80346-8"},{"key":"e_1_2_1_75_2","first-page":"330","article-title":"Amiodarone: a unique antiarrhythmic agent","volume":"2","author":"Sloskey GE","year":"1983","journal-title":"Clin Pharm"},{"key":"e_1_2_1_76_2","first-page":"434","volume-title":"Cardiac arrhythmia: mechanisms, diagnosis and management","author":"Naccarelli GV","year":"1995"},{"issue":"2","key":"e_1_2_1_77_2","first-page":"243","article-title":"Pharmacodynamics and pharmacokinetics of the novel class III antiarrhythmic drug UK\u201068,798 in man","volume":"31","author":"Tham TCK","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199220002-00015"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.149"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.86.1.75"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(84)80327-7"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90076-6"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00163.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.14.1749"},{"key":"e_1_2_1_85_2","volume-title":"Tikosyn (dofetilide) product information","author":"Pfizer Labs.","year":"1999"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90200-5"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00275-1"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00078-2"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00168-X"},{"key":"e_1_2_1_90_2","first-page":"103","article-title":"Maintenance of sinus rhythm after elective cardioversion from chronic stable atrial fibrillation amiodarone compared with quinidine","volume":"5","author":"O'Keefe DB","year":"1984","journal-title":"Br Heart J"},{"key":"e_1_2_1_91_2","first-page":"431","article-title":"Amiodarone versus quinidine in the prophylaxis of atrial fibrillation","volume":"36","author":"Vitolo E","year":"1981","journal-title":"Acta Cardiol"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90294-W"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421302"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00220-9"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05281-1"},{"key":"e_1_2_1_96_2","first-page":"I\u2010633","article-title":"Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: the EMERALD study [abstr]","volume":"98","author":"Greenbaum RA","year":"1998","journal-title":"Circulation"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.19.2385"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)02149-6"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09145-3"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)08171-8"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91895-3"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(85)90238-8"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-9-199505010-00008"},{"key":"e_1_2_1_104_2","first-page":"272","article-title":"High frequency of amiodarone pulmonary toxicity: role of diffusion capacity [abstr]","volume":"72","author":"Magro SA","year":"1985","journal-title":"Circulation"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.86.4.541"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199301000-00014"},{"key":"e_1_2_1_107_2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1378\/chest.111.5.1446","article-title":"Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis","volume":"111","author":"Goldstein I","year":"1997","journal-title":"Chest"},{"key":"e_1_2_1_108_2","volume-title":"Betapace\u2010AF (sotalol) product information","author":"Berlex Laboratories.","year":"2000"},{"key":"e_1_2_1_109_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0022-3565(25)21870-5","article-title":"Frequency\u2010dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers","volume":"229","author":"Nattel S","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.81.2.686"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.72.1.75"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1922"},{"key":"e_1_2_1_113_2","first-page":"I\u2010633","article-title":"Azimilide treatment of atrial fibrillation [abstr]","volume":"98","author":"Pritchett E","year":"1998","journal-title":"Circulation"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.20.1514.34484","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.20.1514.34484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:30:25Z","timestamp":1761067825000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.20.1514.34484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1592\/phco.21.20.1514.34484"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.20.1514.34484","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}